 <h1>Sprycel Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>dasatinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about dasatinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Sprycel.</p><h2>In Summary</h2><p><b>Common side effects of Sprycel include:</b> pericardial effusion, pleural effusion, pulmonary edema, dyspnea, fluid retention, and gastrointestinal hemorrhage. <b>Other side effects include:</b> anasarca.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dasatinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dasatinib (the active ingredient contained in Sprycel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dasatinib:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bloody or black, tarry stools</li>
<li>body aches or pain</li>
<li>burning, tingling, numbness, or pain in the hands, arms, feet, or legs</li>
<li>chest pain</li>
<li>chills</li>
<li>constipation</li>
<li>cough</li>
<li>coughing up blood</li>
<li>decrease in the amount of urine</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>fainting</li>
<li>fast, slow, or irregular heartbeat</li>
<li>fever</li>
<li>full or bloated feeling</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nasal congestion</li>
<li>noisy or rattling breathing</li>
<li>nosebleeds</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pressure in the stomach</li>
<li>prolonged bleeding from cuts</li>
<li>red or dark brown urine</li>
<li>runny nose</li>
<li>sensation of pins and needles</li>
<li>severe stomach pain</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stabbing pain</li>
<li>swelling of the abdominal or stomach area</li>
<li>swelling of the face, fingers, hands, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>weakness in the arms, hands, legs, or feet</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blue lips and fingernails</li>
<li>chest discomfort</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>difficult or fast breathing</li>
<li>dilated neck veins</li>
<li>increased sweating</li>
<li>irregular breathing</li>
<li>nausea</li>
<li>swelling in the legs and ankles</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>blurred vision</li>
<li>cloudy or bloody urine</li>
<li>diarrhea</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>nervousness</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>pounding in the ears</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sudden weakness in the arms or legs</li>
<li>sudden, severe chest pain</li>
<li>tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dasatinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bone pain</li>
<li>cracked lips</li>
<li>difficulty with moving</li>
<li>difficulty with swallowing</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>muscle aching, cramping, or stiffness</li>
<li>pain</li>
<li>skin rash</li>
<li>stomach pain</li>
<li>swollen joints</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dasatinib: oral tablet</i></p><h3>Hematologic</h3><p>In the phase III dose optimization study in patients with chronic phase CML, grade 3 or 4 myelosuppression occurred more frequently in patients treated with the 70 mg twice daily regimen than in those treated with a 100 mg once daily regimen.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hemorrhage (11 to 26%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia, pancytopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): CNS bleeding</p>
<p>Rare (Less than 0.1%): Aplasia pure red cell<sup>[Ref]</sup></p><h3>General</h3><p>The most common side effects included fluid retention, musculoskeletal pain, diarrhea, rash, and headache.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (18 to 31%), vomiting (11 to 16%), nausea (18 to 24%), abdominal pain (12%)</p>
<p><b>Common</b> (1% to 10%): Enterocolitis infection, gastrointestinal bleeding, neutropenic colitis, gastritis, mucositis, stomatitis, dyspepsia, abdominal distension, constipation, oral soft tissue disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, upper gastrointestinal ulcer, esophagitis, ascites, anal fissure, dysphagia</p>
<p>Rare (Less than 0.1%): Protein-losing gastroenteropathy, ileus</p>
<p><b>Postmarketing reports</b>: Fatal gastrointestinal hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (13 to 33%)</p>
<p><b>Common</b> (1% to 10%): Neuropathy, peripheral neuropathy, dizziness, dysgeusia, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope, amnesia, tremor</p>
<p>Rare (Less than 0.1%): Cerebrovascular accident, transient ischemic attack, convulsion, optic neuritis, seventh nerve paralysis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (11 to 22%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm, chills</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis, muscle inflammation, tendonitis, blood creatine phosphokinase increased<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Pleural effusion (11 to 24%), dyspnea (15 to 24%), cough</p>
<p><b>Common</b> (1% to 10%): Pneumonia (including bacterial, viral, fungal), upper respiratory tract infection, pulmonary edema, pulmonary hypertension, lung infiltration, pneumonitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, asthma</p>
<p>Rare (Less than 0.1%): Acute respiratory distress syndrome</p>
<p><b>Postmarketing reports</b>: Pulmonary embolism, interstitial lung disease, pulmonary arterial hypertension<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia, appetite disturbances, hyperuricemia, weight decreased, weight increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoalbuminemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatitis, cholecystitis, cholestasis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Results from phase II single arm clinical studies of 911 patients reported QT prolongation in 9 patients.  Three patients (less than 1%) experienced a QTcF greater than 500 milliseconds.  </p>
<p></p>
<p>In the phase III dose optimization study in patients with chronic phase CML, pleural effusion and congestive cardiac failure/cardiac dysfunction occurred more frequently in the 70 mg twice a day regimen than in those treated with a 100 mg once daily regimen.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Congestive heart failure, cardiac dysfunction, pericardial effusion, arrhythmia, tachycardia, palpitations, hypertension, chest pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction, electrocardiogram QT prolongation, pericarditis, ventricular arrhythmia, ventricular tachycardia, angina pectoris, cardiomegaly, hypotension</p>
<p><b>Rare</b> (less than 0.1%): Cor pulmonale, myocarditis, acute coronary syndrome</p>
<p><b>Postmarketing reports</b>: Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin rash (15 to 21%)</p>
<p><b>Common</b> (1% to 10%): Flushing, alopecia, dermatitis, eczema, pruritus, acne, dry skin, urticaria, hyperhidrosis, contusion</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute febrile neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthesia syndrome </p>
<p>Rare (Less than 0.1%): Livedo reticularis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Fluid retention (21 to 42%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Renal failure, urinary frequency, proteinuria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (19 to 26%), superficial edema (10 to 21%), pyrexia (11 to 18%)</p>
<p><b>Common</b> (1% to 10%): Tinnitus, pain, generalized edema, asthenia</p>
<p><b>Uncommon</b> (0.1% to 10%): Vertigo, thrombophlebitis, gynecomastia, irregular menstruation, malaise, temperature intolerance</p>
<p><b>Postmarketing reports</b>: Deep vein thrombosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anxiety, confusion, affect lability, libido decreased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Erythema nodosum, unspecified hypersensitivity reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Visual disturbance, blurred vision, reduction in visual acuity, dry eye</p>
<p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis</p>
<p>Rare (Less than 0.1%): Visual impairment<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (including bacterial, viral, fungal, non-specified) (10 to 14%)</p>
<p><b>Common</b> (1% to 10%): Sepsis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Gleevec vs Sprycel vs Tasigna - how do they compare?</li>
<li>Is Sprycel a chemotherapy drug?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Sprycel (dasatinib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>16 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sprycel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Chronic Myelogenous Leukemia</li>
<li>Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dasatinib: oral tablet</i></p><h3>Hematologic</h3><p>In the phase III dose optimization study in patients with chronic phase CML, grade 3 or 4 myelosuppression occurred more frequently in patients treated with the 70 mg twice daily regimen than in those treated with a 100 mg once daily regimen.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hemorrhage (11 to 26%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia, pancytopenia</p><p><b>Uncommon</b> (0.1% to 1%): CNS bleeding</p><p>Rare (Less than 0.1%): Aplasia pure red cell<sup>[Ref]</sup></p><h3>General</h3><p>The most common side effects included fluid retention, musculoskeletal pain, diarrhea, rash, and headache.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (18 to 31%), vomiting (11 to 16%), nausea (18 to 24%), abdominal pain (12%)</p><p><b>Common</b> (1% to 10%): Enterocolitis infection, gastrointestinal bleeding, neutropenic colitis, gastritis, mucositis, stomatitis, dyspepsia, abdominal distension, constipation, oral soft tissue disorder</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, upper gastrointestinal ulcer, esophagitis, ascites, anal fissure, dysphagia</p><p>Rare (Less than 0.1%): Protein-losing gastroenteropathy, ileus</p><p><b>Postmarketing reports</b>: Fatal gastrointestinal hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (13 to 33%)</p><p><b>Common</b> (1% to 10%): Neuropathy, peripheral neuropathy, dizziness, dysgeusia, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Syncope, amnesia, tremor</p><p>Rare (Less than 0.1%): Cerebrovascular accident, transient ischemic attack, convulsion, optic neuritis, seventh nerve paralysis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (11 to 22%)</p><p><b>Common</b> (1% to 10%): Arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm, chills</p><p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis, muscle inflammation, tendonitis, blood creatine phosphokinase increased<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Pleural effusion (11 to 24%), dyspnea (15 to 24%), cough</p><p><b>Common</b> (1% to 10%): Pneumonia (including bacterial, viral, fungal), upper respiratory tract infection, pulmonary edema, pulmonary hypertension, lung infiltration, pneumonitis</p><p><b>Uncommon</b> (0.1% to 1%): Bronchospasm, asthma</p><p>Rare (Less than 0.1%): Acute respiratory distress syndrome</p><p><b>Postmarketing reports</b>: Pulmonary embolism, interstitial lung disease, pulmonary arterial hypertension<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Anorexia, appetite disturbances, hyperuricemia, weight decreased, weight increased</p><p><b>Uncommon</b> (0.1% to 1%): Hypoalbuminemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatitis, cholecystitis, cholestasis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Results from phase II single arm clinical studies of 911 patients reported QT prolongation in 9 patients.  Three patients (less than 1%) experienced a QTcF greater than 500 milliseconds.  </p><p></p><p>In the phase III dose optimization study in patients with chronic phase CML, pleural effusion and congestive cardiac failure/cardiac dysfunction occurred more frequently in the 70 mg twice a day regimen than in those treated with a 100 mg once daily regimen.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Congestive heart failure, cardiac dysfunction, pericardial effusion, arrhythmia, tachycardia, palpitations, hypertension, chest pain</p><p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction, electrocardiogram QT prolongation, pericarditis, ventricular arrhythmia, ventricular tachycardia, angina pectoris, cardiomegaly, hypotension</p><p><b>Rare</b> (less than 0.1%): Cor pulmonale, myocarditis, acute coronary syndrome</p><p><b>Postmarketing reports</b>: Atrial fibrillation, atrial flutter<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin rash (15 to 21%)</p><p><b>Common</b> (1% to 10%): Flushing, alopecia, dermatitis, eczema, pruritus, acne, dry skin, urticaria, hyperhidrosis, contusion</p><p><b>Uncommon</b> (0.1% to 1%): Acute febrile neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthesia syndrome </p><p>Rare (Less than 0.1%): Livedo reticularis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Fluid retention (21 to 42%)</p><p><b>Uncommon</b> (0.1% to 1%): Renal failure, urinary frequency, proteinuria<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (19 to 26%), superficial edema (10 to 21%), pyrexia (11 to 18%)</p><p><b>Common</b> (1% to 10%): Tinnitus, pain, generalized edema, asthenia</p><p><b>Uncommon</b> (0.1% to 10%): Vertigo, thrombophlebitis, gynecomastia, irregular menstruation, malaise, temperature intolerance</p><p><b>Postmarketing reports</b>: Deep vein thrombosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Anxiety, confusion, affect lability, libido decreased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Erythema nodosum, unspecified hypersensitivity reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Visual disturbance, blurred vision, reduction in visual acuity, dry eye</p><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis</p><p>Rare (Less than 0.1%): Visual impairment<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (including bacterial, viral, fungal, non-specified) (10 to 14%)</p><p><b>Common</b> (1% to 10%): Sepsis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Gleevec vs Sprycel vs Tasigna - how do they compare?</li>
<li>Is Sprycel a chemotherapy drug?</li>
</ul><h2>More about Sprycel (dasatinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>16 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sprycel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Chronic Myelogenous Leukemia</li>
<li>Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>